Pulmonary Research & Clinical Trials
Our Pulmonary teams are committed to continuing improvement on care initiatives and solutions for chronic respiratory conditions. They lead several ongoing clinical trials, and aid in the advancement of new technology, diagnostic solution and medication management opportunities.
For Patients
If you have been diagnosed with pulmonary diseases such as Asthma, Chronic Obstructive Pulmonary Disease (COPD), Pulmonary Fibrosis, or Pulmonary Hypertension you may be eligible to participate in a clinical research trial. Clinical research trials take place at both the East and West locations for The Oregon Clinic Pulmonary, Critical Care & Sleep Medicine.
There are different types of clinical trials you can be involved with. To learn more about the world of research, we highly recommend reading more on the U.S. National Library of Medicine website by clicking here.
If you are interested in participating in a research trial, please call the contact info that corresponds with your diagnosed disease for more information.
Pulmonary, Critical Care & Sleep Medicine East
- Asthma
- COPD
- Lung Nodule
- Idiopathic Pulmonary Fibrosis
- Interstitial Lung Disease
- Pulmonary Hypertension
Contact: Meg Day | 503-963-3182 | Email
Pulmonary, Critical Care & Sleep Medicine – West
- Asthma
- Pulmonary Hypertension
Contact: Pulmonary, Critical Care & Sleep Medicine West | 503-297-3778
For Health Professionals
Avalyn-AP01-007-Progressive Pulmonary Fibrosis
Meg Day I 503-963-3182 I Email or Johanna Donnelly I 503-963-3169 I Email
A randomized, double-blind, placebo-controlled, Phase 2b study evaluating the safety and efficacy of Pirfenidone solution for Inhalation (AAP01) in subjects with Progressive Pulmonary Fibrosis (PPF)
Enrolling subjects 18+ years old, with interstitial lung disease of known or unknown etiology other than IPF. Physiological evidence of disease progression with 5-10% relative decline in FVC and worsening respiratory symptoms or HRCT evidence of disease progression. FVC of > 45% of predicted and DLcO of > 30% of predicted at screening. Must not be on oral pirfenidone within three months of screening or during the trial.
Biodesix BDX-CD-003 (Altitude)
Meg Day I 503-963-3182 I Email
A multicenter, randomized controlled trial, prospectively evaluating the clinical utility of the Nodify XL2®Proteomic Classifier in newly discovered low to moderate risk lung nodules
Enrolling 40+ year old subjects with newly identified solid lung nodules between 8 and 30mm. A CT scan identifying the lung nodule of concern must have been performed within 60 days of enrollment. Subjects with prior history of lung cancer are excluded.
PHAR Pulmonary Hypertension Association Registry
Meg Day I 503-963-3182 I Email
A multicenter, prospective registry of newly evaluated patients at PHCCs in the United States who have either PAH or CTEPH
Baseline information will be collected at the time of initial evaluation at the PHCC with follow-up data collected at approximately 6-month intervals.
Vicore-VP-C21-011- Idiopathic Pulmonary Fibrosis
Meg Day I 503-963-3182 I Email or Johanna Donnelly I 503-963-3169 I Email
A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial evaluating the efficacy and safety of 2 doses of buloxibutid over 52 weeks in people with idiopathic pulmonary fibrosis
Enrolling subjects with IPF diagnosed within the past 5 years. Cannot be on pirfenidone (Esbriet), but treatment with stable dose of nintedanib (Ofev) is allowed. Will need to have an FVC of > 50% of predicted and DLcO of > 35% of predicted at screening. No exacerbations within 3 months of screening.